Next Article in Journal
Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence
Previous Article in Journal
Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies
Article

EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma

Pharmaceutical Sciences, St. John’s University, Queens, NY 11439, USA
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(10), 504; https://doi.org/10.3390/pharmaceutics11100504
Received: 31 July 2019 / Revised: 18 September 2019 / Accepted: 19 September 2019 / Published: 1 October 2019
The clinical outcomes of malignant melanoma have improved with the introduction of mitogen-activated protein kinase kinase (MEK) inhibitors. However, off-target toxicities of the MEK inhibitor trametinib (TMB) often result in dose interruption and discontinuation of therapy. The purpose of this study was to anchor a physically stable EphrinA1-mimicking peptide known as YSA (YSAYPDSVPMMS) on TMB-loaded PEGylated nanoliposomes (YTPLs), and evaluate them in BRAFV600E-mutated parent cells (lines A375 and SK-MEL-28) and vemurafenib-resistant cells lines (A375R and SK-MEL-28R) in melanoma. TMB-loaded PEGylated liposomes (TPL) functionalized with nickel-chelated phospholipids were prepared using a modified hydration method. The hydrodynamic diameter and zeta potential values of optimized YTPL were 91.20 ± 12.16 nm and –0.92 ± 3.27 mV, respectively. The drug release study showed TPL did not leak or burst release in 24 h. The hemolysis observed was negligible at therapeutic concentrations of TMB. A differential scanning calorimetry (DSC) study confirmed that TMB was retained in a solubilized state within lipid bilayers. YTPL showed higher intracellular uptake in parental cell lines compared to vemurafenib-resistant cell lines. Western blot analysis and a cytotoxicity study with the EphA2 inhibitor confirmed a reduction in EphA2 expression in resistant cell lines. Thus, EphA2 receptor-targeted nanoliposomes can be useful for metastatic melanoma-specific delivery of TMB. View Full-Text
Keywords: EphA2 receptor; PEGylated nanoliposomes; melanoma cancer; trametinib EphA2 receptor; PEGylated nanoliposomes; melanoma cancer; trametinib
Show Figures

Figure 1

MDPI and ACS Style

Fu, Y.; Rathod, D.; Abo-Ali, E.M.; Dukhande, V.V.; Patel, K. EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma. Pharmaceutics 2019, 11, 504. https://doi.org/10.3390/pharmaceutics11100504

AMA Style

Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K. EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma. Pharmaceutics. 2019; 11(10):504. https://doi.org/10.3390/pharmaceutics11100504

Chicago/Turabian Style

Fu, Yige, Drishti Rathod, Ehab M. Abo-Ali, Vikas V. Dukhande, and Ketan Patel. 2019. "EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma" Pharmaceutics 11, no. 10: 504. https://doi.org/10.3390/pharmaceutics11100504

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop